CogState Ltd represents a set of core values and a corporate philosophy that drive its operations. The company is committed to innovation, delivering cutting-edge solutions in the fields of cognitive assessment and clinical trials. CogState prioritizes integrity, ensuring transparent and ethical practices in all aspects of its business. With a focus on collaboration, CogState fosters strong partnerships to drive mutual success. The company values dedication to excellence, constantly striving for improvement and delivering high-quality products and services. CogState fosters a customer-centric approach, prioritizing customer satisfaction and delivering tailored solutions. Overall, CogState Ltd embodies a commitment to innovation, integrity, collaboration, excellence, and customer-centricity in its corporate philosophy.

CogState Ltd is primarily present in Australia, the United States, and Europe.

CogState Ltd has achieved several significant milestones in its history. One key achievement is the development and commercialization of its pioneering cognitive testing technology, known as the CogState Computerized Cognitive Assessment Tool (CCAT). This innovative tool is widely utilized in clinical trials and research studies worldwide, enabling precise and objective measurement of cognitive function. Additionally, CogState Ltd has successfully established strategic partnerships with leading pharmaceutical companies, academic institutions, and healthcare providers, facilitating the widespread adoption of its solutions. The company continues to thrive through ongoing research and development, further cementing its position as a global leader in cognitive assessment technology.

CogState Ltd is a renowned company with a rich history and background. Founded in 1999, CogState specializes in cognitive testing and offers innovative solutions to improve brain health assessment. With its headquarters in Melbourne, Australia, the company has expanded its global presence, serving various sectors including pharmaceuticals, biotechnology, and academic research. CogState has developed cutting-edge technologies and software platforms to deliver accurate and efficient cognitive assessments, benefiting patients, researchers, and professionals worldwide. Known for its advanced cognitive testing methods and commitment to enhancing brain health, CogState Ltd has established itself as a trusted industry leader.

The main competitors of CogState Ltd in the market are Cambridge Cognition Holdings PLC, Neurotrack Technologies Inc., and CogniFit Ltd. These companies also specialize in cognitive assessment and provide similar solutions and services. However, CogState Ltd distinguishes itself through its innovative technologies and partnerships, including collaborations with leading pharmaceutical companies. With its strong focus on enhancing the understanding and measurement of cognitive function, CogState Ltd continues to remain competitive in the market and deliver valuable solutions to its clients.

CogState Ltd is primarily active in the healthcare and pharmaceutical industries.

CogState Ltd is a leading provider of cognitive testing services for clinical trials, academic research, and healthcare. The company's business model revolves around using their digital tools and technologies to measure and enhance cognitive function in patients. By collaborating with pharmaceutical companies, academic institutions, and healthcare organizations, CogState Ltd aims to improve patient outcomes and accelerate the development of new treatments. With their expertise and extensive database, CogState Ltd offers customized solutions and prognostic insights to address the cognitive challenges faced in various industries.

CogState의 P/E 비율은 29.24입니다.

CogState의 P/S 비율은 3.16입니다.

CogState에 대한 AlleAktien 품질 점수는 3/10입니다.

예상되는 CogState 매출은 43.04 백만 USD입니다.

예상되는 CogState 이익은 4.66 백만 USD입니다.

CogState Ltd is an innovative company specializing in the development and marketing of cognitive testing solutions. The company offers a wide range of products and services that can be used in the fields of pharmaceutical research, clinical diagnostics, and sports performance optimization. The three main business divisions of CogState Ltd include research and development of cognitive tests, clinical diagnostics and monitoring of patients with neurodegenerative disorders, and solutions for improving sports performance. The company's products are rooted in today's technology, as they are exclusively offered online. They allow for remote diagnosis and supervision of patients, saving time for therapists and improving diagnostic accuracy. The company's proprietary software platform enables researchers to effectively manage their studies and present study results in a concise format. CogState Ltd has a strategy in place to continue offering unique and expanding product offerings, allowing the company to remain a strong competitor in the industry.

CogState은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

CogState의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

CogState의 ISIN은 AU000000CGS8입니다.

CogState의 티커는 CGS.AX입니다.

지난 12개월 동안 CogState은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 CogState은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

CogState의 현재 배당 수익률은 입니다.

CogState은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

CogState은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

CogState은 '건강' 섹터에 속합니다.

CogState의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 CogState는 0 USD를 배당금으로 지급했습니다.

CogState의 배당금은 USD에 지급됩니다.